Jinling Xu

Jinling Xu has worked in the biotechnology industry since 2000. Jinling began their career as a Research Technologist and Lab Manager at the Department of Molecular Biology in Massachusetts General Hospital. In 2006, they moved to the University of Maryland as a Senior Research Associate. In 2010, they joined OriGene Technologies, Inc. as a Senior Research Associate and Lab Manager where they generated more than 10 rabbit monoclonal antibodies and produced around 70 rabbit monoclonal antibodies in large scale. In 2018, they joined NextCure, Inc. as a Scientist II, where they performed upstream and downstream tasks in the protein production process. In 2021, they moved to MacroGenics, Inc. as an Associate Scientist II and in 2022, they joined OncoC4, Inc. as a Scientist II.

Jinling Xu completed their undergraduate studies at the College of Biology, China Agriculture University, where they earned a Bachelor of Science degree in Animal Physiology & Biochenistry between 1984 and 1988. Jinling then went on to pursue a Master of Science degree at the Graduate School of Chinese Academy of Agriculture Sciences, which they completed in 1991 in the field of Animal Biotechnology.